Document is current
Any future updates will be listed below
-
Authors
Bonsor, Daniel A. https://orcid.org/0000-0001-5746-6002
Finci, Lorenzo I.
Potter, Jacob R. https://orcid.org/0000-0002-5849-6219
Young, Lucy C.
Wall, Vanessa E. https://orcid.org/0000-0002-6972-239X
Goldstein de Salazar, Ruby
Geis, Katie R.
Stephens, Tyler
Finney, Joseph
Nissley, Dwight V. https://orcid.org/0000-0001-7523-116X
McCormick, Frank https://orcid.org/0000-0002-6619-7120
Simanshu, Dhirendra K. https://orcid.org/0000-0002-9717-4618
- License Information
-
More Information
Article History
Received: 5 May 2025
Accepted: 18 December 2025
First Online: 10 January 2026
Competing interests
: F.M. is a consultant for Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, Pfizer, Daiichi Sankyo, Amgen, PMV Pharma, OPNA-IO, and Quanta Therapeutics. He has received research grants from Boehringer–Ingelheim, and is a consultant for and cofounder of BridgeBio Pharma. The remaining authors declare no competing interests.
